Icon Plc (NASDAQ:ICLR) – Investment analysts at SunTrust Banks lowered their FY2017 earnings estimates for Icon in a research note issued on Monday. SunTrust Banks analyst S. Draper now forecasts that the medical research company will post earnings per share of $5.25 for the year, down from their prior estimate of $5.37. SunTrust Banks has a “Buy” rating and a $133.00 price objective on the stock. SunTrust Banks also issued estimates for Icon’s Q4 2017 earnings at $1.42 EPS, FY2018 earnings at $6.08 EPS and FY2019 earnings at $6.96 EPS.
Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The company had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same quarter last year, the firm posted $1.19 EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis.
Shares of Icon (NASDAQ ICLR) opened at $112.68 on Tuesday. Icon has a twelve month low of $76.46 and a twelve month high of $124.48. The firm has a market capitalization of $6,171.70, a PE ratio of 21.84, a P/E/G ratio of 1.62 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31.
Hedge funds and other institutional investors have recently modified their holdings of the business. GRATRY & Co LLC boosted its stake in Icon by 5.1% in the 3rd quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock worth $3,433,000 after purchasing an additional 1,474 shares during the period. GSA Capital Partners LLP boosted its position in shares of Icon by 116.3% during the 2nd quarter. GSA Capital Partners LLP now owns 9,337 shares of the medical research company’s stock valued at $913,000 after acquiring an additional 5,020 shares during the last quarter. BT Investment Management Ltd bought a new stake in shares of Icon during the 3rd quarter valued at about $325,000. Insight Capital Research & Management Inc. bought a new stake in shares of Icon during the 3rd quarter valued at about $1,359,000. Finally, NorthCoast Asset Management LLC boosted its position in shares of Icon by 23.4% during the 3rd quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock valued at $2,052,000 after acquiring an additional 3,419 shares during the last quarter. Institutional investors and hedge funds own 89.65% of the company’s stock.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.